Volume 7, Issue 1, February 2019, Page: 22-30
Rational Design and Construction of a Knock-Out Vector for Targeting the Decoy Type 2 Interleukin -1 Receptor
Faith Owabhel Robert, Department of Biochemistry, Niger Delta University, Wilberforce Island, Amassoma, Nigeria
Emmanuel Amabebe, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Received: Jan. 6, 2019;       Accepted: Apr. 2, 2019;       Published: Apr. 22, 2019
DOI: 10.11648/j.ajbls.20190701.15      View  37      Downloads  22
Abstract
Given the limited data describing the phenotype for type 2 interleukin -1 receptor (Il1r2-/-) in mouse strains and based on the decoy role of the gene product (IL-1R2), we hypothesized that IL-1R2 may have a unique but similar inhibitory role to IL-1R antagonist (IL-1Ra) in vivo. Despite the anti-inflammatory function of IL-1R2, its role in disease in vivo remains unclear. Therefore, we designed and implemented a knock-out construct template for a mouse embryonic stem (ES) cell line that can be used to easily make knockout mice. Bacterial artificial chromosome (BAC) clone of Il1r2 from mouse strain AB2.2 and ES cells from same strain were obtained and a long chain PCR was performed to isolate homologous arms containing homologous segments (8kb and 2kb). Short segments were cloned out for use as probe sequences and a construct with deletion in exon 3 was made so it can be removed in vivo. The NeoR in cloning vector was then flanked with loxP elements. The two homologous arms were successfully amplified with a truncation in exon 3 of the gene and the wild type cloning plasmid (p1049) was serially modified with loxP elements. One of the successfully transformed plasmid DNA was used as the starting material for the ligation of the subsequent loxP-PacI linker. This plasmid (p1049XL) was amplified in E. coli DH5α cells and DNA extracted. The loxP-PacI linker was successfully ligated into the plasmid and transformed clones screened with MspI and compared to the virtual digest of the theoretical plasmid containing the insert and subsequently sequenced. This study has provided the basic ingredients for making an Il1r2-deficient mouse in order to adequately characterize the phenotype. By assembling the complete knock out construct from templates already provided in this study for the knock out in embryonic stem cells, Il1r2-deficient mice could be made.
Keywords
IL-1R2, Embryonic Stem Cell, BAC Clone, Long Chain PCR, Loxp Elements, Phenotype, Homologous Segments
To cite this article
Faith Owabhel Robert, Emmanuel Amabebe, Rational Design and Construction of a Knock-Out Vector for Targeting the Decoy Type 2 Interleukin -1 Receptor, American Journal of Biomedical and Life Sciences. Vol. 7, No. 1, 2019, pp. 22-30. doi: 10.11648/j.ajbls.20190701.15
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Martin P, Palmer G, Rodriguez E, Seemayer CA, Palomo J, Talabot-Ayer D, et al. (2017). Deficiency in IL-1 Receptor Type 2 Aggravates K/BxN Serum Transfer-Induced Arthritis in Mice but Has No Impact on Systemic Inflammatory Responses. J Immunol. 198(7):2916-2926. doi: 10.4049/jimmunol.1600855.
[2]
Peters VA, Joesting JJ, Freund GG. (2013). IL-1 receptor 2 (IL-1R2) and its role in immune regulation. Brain Behav Immun. 32:1–8. http://doi.org/10.1016/j.bbi.2012.11.006
[3]
McMahan CJ, Slack JL, Mosley B, Cosman SD, Lupton LL, Brunton CE, et al. (1991). A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J. 10(10):2821-2832.
[4]
Burger D, Chicheportiche R, Giri JG, Dayer JM. (1995). The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 96(1):38-41. doi: 10.1172/JCI118045
[5]
Malinowsky D, Lundkvist J, Laye S, Bartfai T. (1998). Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett. 429(3):299–302.
[6]
Lang D, Knop J, Wesche H, Raffetseder U, Kurrle R, Boraschi D, et al. (1998). The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol. 161(12):6871–6877.
[7]
Martin P, Palmer G, Vigne S, Lamacchia C, Rodriguez E, Talabot-Ayer D, et al. (2013). Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leukoc Biol. 94(4):791-802. doi: 10.1189/jlb.0113035
[8]
Colotta F, Orlando S, Fadlon EJ, Sozzani S, Matteucci C, Mantovani A. (1995). Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells. J Exp Med. 181(6):2181-6.
[9]
Giri JG, Wells J, Dower SK, McCall CE, Guzman RN, Slack J, et al. (1994). Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol. 153(12):5802-5809.
[10]
Orlando S, Matteucci C, Fadlon EJ, Buurman WA, Bardella MT, Colotta F, et al. (1997). TNF-alpha, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J Immunol. 158(8):3861-3868.
[11]
Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, et al. (2003). The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 18(1):87–96.
[12]
Akoum A, Jolicoeur C, Kharfi A, Aube M. (2001). Decreased expression of the decoy interleukin-1 receptor type II in human endometriosis. Am J Pathol. 158:481–489. doi: 10.1016/S0002-9440(10)63990-9
[13]
Kharfi A, Akoum A. (2002). Soluble interleukin-1 receptor type II blocks monocyte chemotactic protein-1 secretion by U937 cells in response to peripheral blood serum of women with endometriosis. Fertil Steril. 78(4):836–842.
[14]
Akoum A, Lawson C, Herrmann-Lavoie C, Maheux R. (2007). Imbalance in the expression of the activating type I and the inhibitory type II interleukin 1 receptors in endometriosis. Hum Reprod. 22:1464–1473. doi: 10.1093/humrep/dem021
[15]
Lawson C, Bourcier N, Al-Akoum M, Maheux R, Naud F, Akoum A. (2008). Abnormal interleukin 1 receptor types I and II gene expression in eutopic and ectopic endometrial tissues of women with endometriosis. J Reprod Immunol. 77(1):75-84.
[16]
Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. (2007). Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem. 282(16):11982-95.
[17]
Garlind A, Brauner A, Hojeberg B, Basun H, Schultzberg M. (1999). Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer’s disease patients. Brain Res. 826(1):112–116.
[18]
Rauschmayr T, Groves RW, Kupper TS. (1997). Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci USA. 94(11):5814-5819.
[19]
Chou H-H, Takashiba S, Maeda H, Naruishi K, Nishimura F, Arai H et al. (2000). Induction of Intracellular Interleukin-1 β Signals via Type II Interleukin-1 Receptor in Human Gingival Fibroblasts. J Dent Res. 79(9):1683-1688. doi.org/10.1177/00220345000790090801
[20]
Mulligan, R. C., and P. Berg. (1981). Factors governing the expression of a bacterial gene in mammalian cells. Mol. Cell. Biol. 1:449-459.
Browse journals by subject